Please assess the completion status of the following clinical trial:

Trial Title: GLP-1/Basal Insulin Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* T2DM, age 18-85 years, documentation of basal insulin therapy for minimum of one year prior to GLP-1 initiation, and addition of weekly exenatide or daily liraglutide added to basal insulin therapy~Exclusion Criteria:~* Type 1 diabetes, patients receiving prescription medications for weight loss, and initiation of additional diabetes, hypertension or cholesterol drugs during the follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Weekly GLP-1 therapy: exenatide (Type: None): Patients receiving weekly exenatide
- Daily GLP-1 therapy liraglutide (Type: None): Patients receiving daily liraglutide

Based on this trial design, predict the completion outcome and termination type (if applicable).